Overview

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Status:
Terminated

Trial end date:
2019-05-10

Target enrollment:

Participant gender:

Summary

This is a first in human, non-randomized, open-label, dose escalation study to investigate the safety, pharmacokinetics, immunogenicity and pharmacodynamics of repeat doses of KHK2823.

Phase:

Phase 1

Details

Lead Sponsor:

Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin, Inc.